View and download slide summaries of the latest original articles focusing on therapies in immune-mediated inflammatory diseases including rheumatology, dermatology, and gastroenterology. All materials produced by the team are subsequently reviewed and approved by individual Steering Committee members.
N Engl J Med. 2024;391:1119-1129 doi: 10.1056/NEJMoa23140
Sands et al. demonstrated that 12-week treatment of tulisokibart, a monoclonal antibody targeting TL1A, significantly improved clinical remission rates compared to placebo in patients with moderate-to-severe ulcerative colitis.
Clin Exp Dermatol. 2024 Sep 18;49:1232-1234 doi: 10.1093/ced/llae16
Napolitano et al. conducted a retrospective analysis on patients with moderate-to-severe psoriasiform atopic dermatitis (AD) treated with JAK inhibitors, showing significant improvements in disease severity scores (EASI, P-NRS, DLQI) by Week 4, with 95% of patients achieving EASI-75 and 86% achieving EASI-90 by Week 24.
Journal of Translational Medicine 2024;22:795
Su et al. conducted a comprehensive systematic review and network meta-analysis to assess the efficacy and safety of therapies for difficult-to-treat (D2T) RA. They found that tocilizumab and rituximab had superior efficacy and safety profiles, with 8mg every 4 weeks of tocilizumab identified as the optimal therapeutic dose.
Inflammopharmacology (2024) 32:3229–46 doi: 10.1007/s10787-024-01563-3
Kandeel et al. compared JAK inhibitors and TNF inhibitors in RA. JAK inhibitors demonstrated better functional improvement via HAQ-DI but showed insignificant difference in CDAI compared to TNF inhibitors; both classes had similar safety.
JJC 2024;18;391(3):2170 82. DOI 10.1093/ecco-jcc/jjae038
Peyrin-Biroulet et al. evaluated the efficacy and safety of etrasimod in patients with moderately to severely active isolated proctitis, demonstrating significant improvement in clinical outcomes compared to placebo. The study reported a favourable safety profile, making etrasimod a viable treatment option for this population.
Arthritis Rheumatol 2024 Epub ahead of print doi: 10.1002/art.42974
Pacheco et al. demonstrated that, compared with axSpA patients who respond to secukinumab, patients who do not respond show increased IL-17A-producing cells and have a more pronounced type 1 IFN signature, indicating a larger inflammatory burden.
Journal Reference: Arthritis Res Ther 2024;26:143 doi: 10.1186/s13075-024-03358-x
van Vollenhoven et al. compared the efficacy and safety of upadacitinib monotherapy to methotrexate monotherapy over five years in methotrexate-naïve patients with rheumatoid arthritis. The study found that upadacitinib provided better long-term efficacy and higher rates of disease activity remission than methotrexate; however, it was associated with higher incidences of adverse events, particularly at the higher dose of 30 mg.
Journal Reference: Rheum. 2024 Epub ahead of print doi: 10.1093/rheumatology/keae455.
Adami et al. conducted a retrospective analysis to evaluate the GC sparing effects of JAKi versus bDMARDs in rheumatoid arthritis patients. They found that JAKi therapy was associated with a significant reduction in GC dose compared with bDMARDs. This suggests that JAKi could be more effective in reducing long-term GC exposure in RA patients.
Rheumatol Ther 2024 Epub ahead of print doi: 10.1007/s40744-024-00695-w
Patients classified as having a high neutrophil-to-lymphocyte ratio (NLR-High) who received filgotinib 200mg + MTX/csDMARDs exhibited consistently better responses after 12 weeks across clinical trials, clinical endpoints, and PROs, compared with NLR-Low patients. Taylor et al. analysed data from the 3 FINCH trials to investigate the potential association of baseline NLR with improved clinical response to filgotinib in MTX-naïve or MTX-experienced RA populations.
Journal Reference: Am J Gastroenterol 2024;119:1365–72 doi: 10.14309/ajg.0000000000002635
A combination of tofacitinib and corticosteroids improved treatment responsiveness and decreased the need for rescue therapy in patients with acute severe ulcerative colitis (ASUC). Singh et al. investigated whether addition of tofacitinib to corticosteroids was superior to corticosteroids alone in patients hospitalised with ASUC.
